Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Recent Progress in Tuberculosis Vaccine Development
share announcement

Recent Progress in Tuberculosis Vaccine Development

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 5651

Special Issue Editor

Dr. Sunhee Lee

E-Mail Website
Guest Editor
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
Interests: host–pathogen interaction; innate immunity; vaccine development; host-directed therapy

Special Issue Information

Dear Colleagues,

Mycobacterium tuberculosis (Mtb), the causative agent of TB, kills more people worldwide than any infectious pathogen. Nonetheless, the only licensed vaccine against TB, Bacille Calmette Guerin (BCG), is approaching its centenary. The development of new vaccines capable of preventing Mtb infection, including multidrug-resistant tuberculosis, is an essential component of the strategy to combat the TB epidemic. 

Many different vaccine candidates and their advanced clinical stages signify an exciting phase in TB vaccine research. Two recent advances in clinical tuberculosis vaccine development have rejuvenated the field. BCG revaccination has shown statistically significant 45% efficacy against sustained Mtb infection in adolescents; and an adjuvanted protein-subunit vaccine based on two TB antigens, M72/AS01E, has presented 54% protection against active pulmonary disease, without evident safety concerns. Additionally, numerous novel vaccine candidates are in preclinical development, including DNA vaccines, recombinant cytomegalovirus (CMV)-based candidates, a variety of live-attenuated or killed mycobacteria-derived candidates, and combination vaccines. 

This recent positive clinical trial data bestow encouraging evidence and represent a critical milestone in global efforts to develop a novel efficacious TB vaccine. Such successes demonstrate that TB vaccine research is on the right track to deliver much-needed advanced vaccine strategies crucial for controlling the global TB epidemic. 

This Special Issue, “TB Vaccine Development”, will present and update the scientific efforts to replace or potentiate BCG in infants and to develop new TB vaccines for adolescents and adults. We welcome submission of manuscripts that investigate: TB vaccine development, strategies to diversify vaccine platforms, new animal models for TB vaccines, reliable models to predict human protection, immunological correlation of protection, limitations in BCG immunity, and breakthrough findings in the basic immunology of Mtb infection to investigate possible targets of vaccine development. We also encourage submissions of manuscripts that explore novel antigens, adjuvant formulations, and routes of vaccination. 

Dr. Sunhee Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Mycobacterium tuberculosis
  • Correlate of protection
  • Routes of vaccination
  • New adjuvant
  • Bacille Calmette Guerin (BCG)
  • Atypical immune response
  • Novel antigens
  • TB vaccine
  • Clinical vaccine trials
  • Innate and adaptive Immunity

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 3799 KiB  
Article
Therapeutic Effect of Subunit Vaccine AEC/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model
by Jinbiao Lu, Xiaonan Guo, Chunhua Wang, Weixin Du, Xiaobing Shen, Cheng Su, Yongge Wu and Miao Xu
Vaccines 2022, 10(5), 825; https://doi.org/10.3390/vaccines10050825 - 23 May 2022
Cited by 17 | Viewed by 2399
Abstract
Tuberculosis (TB), caused by the human pathogen Mycobacterium tuberculosis (Mtb), is an infectious disease that presents a major threat to human health. Bacillus Calmette-Guérin (BCG), the only licensed TB vaccine, is ineffective against latent TB infection, necessitating the development of further [...] Read more.
Tuberculosis (TB), caused by the human pathogen Mycobacterium tuberculosis (Mtb), is an infectious disease that presents a major threat to human health. Bacillus Calmette-Guérin (BCG), the only licensed TB vaccine, is ineffective against latent TB infection, necessitating the development of further TB drugs or therapeutic vaccines. Herein, we evaluated the therapeutic effect of a novel subunit vaccine AEC/BC02 after chemotherapy in a spontaneous Mtb relapse model. Immunotherapy followed 4 weeks of treatment with isoniazid and rifapentine, and bacterial loads in organs, pathological changes, and adaptive immune characteristics were investigated. The results showed slowly increased bacterial loads in the spleen and lungs of mice inoculated with AEC/BC02 with significantly lower loads than those of the control groups. Pathological scores for the liver, spleen, and lungs decreased accordingly. Moreover, AEC/BC02 induced antigen-specific IFN-γ-secreting or IL-2-secreting cellular immune responses, which decreased with the number of immunizations and times. Obvious Ag85b- and EC-specific IgG were observed in mice following the treatment with AEC/BC02, indicating a significant Th1-biased response. Taken together, these data suggest that AEC/BC02 immunotherapy post-chemotherapy may shorten future TB treatment. Full article
(This article belongs to the Special Issue Recent Progress in Tuberculosis Vaccine Development)
►▼ Show Figures

Figure 1

12 pages, 785 KiB  
Article
Identification of Mycobacterium tuberculosis Antigens with Vaccine Potential Using a Machine Learning-Based Reverse Vaccinology Approach
by Blaine Teahan, Edison Ong and Zhenhua Yang
Vaccines 2021, 9(10), 1098; https://doi.org/10.3390/vaccines9101098 - 28 Sep 2021
Cited by 2 | Viewed by 2457
Abstract
Tuberculosis (TB) is the leading cause of death of any single infectious agent, having led to 1.4 million deaths in 2019 alone. Moreover, an estimated one-quarter of the global population is latently infected with Mycobacterium tuberculosis (MTB), presenting a huge pool of potential [...] Read more.
Tuberculosis (TB) is the leading cause of death of any single infectious agent, having led to 1.4 million deaths in 2019 alone. Moreover, an estimated one-quarter of the global population is latently infected with Mycobacterium tuberculosis (MTB), presenting a huge pool of potential future disease. Nonetheless, the only currently licensed TB vaccine fails to prevent the activation of latent TB infections (LTBI). These facts together illustrate the desperate need for a more effective TB vaccine strategy that can prevent both primary infection and the activation of LTBI. In this study, we employed a machine learning-based reverse vaccinology approach to predict the likelihood that each protein within the proteome of MTB laboratory reference strain H37Rv would be a protective antigen (PAg). The proteins predicted most likely to be a PAg were assessed for their belonging to a protein family of previously established PAgs, the relevance of their biological processes to MTB virulence and latency, and finally the immunogenic potential that they may provide in terms of the number of promiscuous epitopes within each. This study led to the identification of 16 proteins with the greatest vaccine potential for further in vitro and in vivo studies. It also demonstrates the value of computational methods in vaccine development. Full article
(This article belongs to the Special Issue Recent Progress in Tuberculosis Vaccine Development)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop